The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial

AIM OF THE STUDY: The BRAF inhibitor vemurafenib has improved progression-free survival and overall survival in patients with BRAFV600-mutation-positive metastatic melanoma. Here we present the results of an open-label safety study with vemurafenib in patients with metastatic melanoma enrolled in Po...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Contemp Oncol (Pozn)
Hoofdauteurs: Rutkowski, Piotr, Kozak, Katarzyna, Mackiewicz, Jacek, Krzemieniecki, Krzysztof, Nawrocki, Sergiusz, Wasilewska-Teśluk, Ewa, Kwinta, Łukasz, Wysocki, Piotr, Koseła-Paterczyk, Hanna, Świtaj, Tomasz
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Termedia Publishing House 2015
Onderwerpen:
Original Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4631301/
https://ncbi.nlm.nih.gov/pubmed/26557775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2015.54082
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items